Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study

por Hattori, Nobutaka, Kamei, Takanori, Ishida, Takayuki, Suzuki, Ippei, Nomoto, Masahiro, Tsuboi, Yoshio
Publicado 2022

Correction: Long-term effects of safinamide adjunct therapy on levodopa-induced dyskinesia in Parkinson’s disease: post-hoc analysis of a Japanese phase III study

por Hattori, Nobutaka, Kamei, Takanori, Ishida, Takayuki, Suzuki, Ippei, Nomoto, Masahiro, Tsuboi, Yoshio
Publicado 2022

Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A post hoc analysis of the SETTLE study

por Bhidayasiri, Roongroj, Koebis, Michinori, Kamei, Takanori, Ishida, Takayuki, Suzuki, Ippei, Cho, Jin Whan, Wu, Shey-Lin
Publicado 2023

Safinamide as an Adjunct to Levodopa in Asian and Caucasian Patients With Parkinson’s Disease and Motor Fluctuations: A Post Hoc Analysis of the SETTLE Study

por Bhidayasiri, Roongroj, Ishida, Takayuki, Kamei, Takanori, Husni, Ryan Edbert, Suzuki, Ippei, Wu, Shey Lin, Cho, Jin Whan
Publicado 2023